CDK4/6 Inhibitor Efficacy in ESR1-Mutant Metastatic Breast Cancer.
Lloyd MR, Brett JO, Carmeli A, Weipert CM, Zhang N, Yu J, Bucheit L, Medford AJ, Wagle N, Bardia A, Wander SA.
Lloyd MR, et al.
NEJM Evid. 2024 May;3(5):EVIDoa2300231. doi: 10.1056/EVIDoa2300231. Epub 2024 Apr 23.
NEJM Evid. 2024.
PMID: 38815172